Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
18 avr. 2024 16h10 HE
|
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001).
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
11 avr. 2024 08h05 HE
|
Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.
Unity Consortium Marks Adolescent Immunization Action Week (AIAW) with activities to help Parents and Adolescents get up to date on Recommended Vaccines
28 mars 2024 08h05 HE
|
Unity Consortium
Unity Consortium marks Adolescent Immunization Action Week, April 1-5, 2024, encouraging parents and adolescents to get up to date on recommended vaccines
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
27 févr. 2024 07h00 HE
|
Purple Biotech Ltd.
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...
Cervical Cancer Studies Outline Innovative Treatment Options For Patients In 2024
15 févr. 2024 11h42 HE
|
Allsup
Belleville, Illinois, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Groundbreaking research studies of the latest cervical cancer treatments are illuminating new paths for patients and highlighting the...
Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
06 févr. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a...
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
05 janv. 2024 16h01 HE
|
Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays
10 nov. 2023 07h00 HE
|
Microbix Biosystems Inc.
Microbix secures a new European collaborator, Ulisse Biomed, in relation to HPV testing and cervical cancer screening.
Microbix QAPs Supporting HPV Testing in Ireland
27 oct. 2023 07h00 HE
|
Microbix Biosystems Inc.
MISSISSAUGA, Ontario, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its...
Point of Care Diagnostics Market to Hit 12.7% CAGR with Glucose Monitoring Products Driving Growth During 2021–2028 | The Insight Partners
26 oct. 2023 07h55 HE
|
The Insight Partners
Pune, India, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Point-of-care testing (POCT) is essential for the rapid detection of analytes near to the patient, which facilitates in disease diagnosis, monitoring,...